Good day, and thank you for standing by. Welcome to the Tarsus Future Potential Growth Drivers webcast. At this time, all participants are in a listen-only mode. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your speaker today, David Nakasone. Good morning, and welcome to our webcast, where we will provide a company update and key growth initiatives for 2025. As a reminder, this webcast is being recorded. Before we begin, I encourage you to go to the investor section of the Tarsus website to view the press release and related materials we will be discussing today. During this call, we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and our actual results may differ materially. For more information, please consult the risk factors contained in our SEC filings. With that, I will turn the call over to our CEO and Chairman, Bobak Azamian. Bobby? Thank you, Dave. And thanks, everybody, for taking the time this morning. We are at an exciting moment in our history, and we're doing this webcast to get across two key points. The first is we see another very strong year of growth ahead for Xdemvy in 2025. We've had a really strong first year, and we want to highlight a couple of things that are going to continue to drive that growth. And the second thing is we're also looking at what's next, and we found another opportunity that looks and feels a lot like DB in ocular rosacea that we want to tell you about today. When we think about what has made us different and made us successful, it really starts with our team. I'm so proud to be joined by our executive team today. And as many of you know, this team has decades of experience in eye care, from development to commercialization, but we've also blended that with some best-in-class biotech experience. That's allowed us to really think differently, ambitiously, about how we can translate biology into patient impact. And one of the things we've done carefully and continue to do at Tarsus is we really listen to what the biology is telling us, but also to what the patients and doctors are telling us. That's allowed us to understand an unmet need that nobody else had before in DB. It allows us to do that again, we believe, in ocular rosacea. And we not only listen, but we also translate that into really differentiated solutions: our products, our approaches. Certainly, that's been the case with our commercialization. And I think many of you know by now that when we say we're going to do something, we do it. We've established a great history of that credibility. So it's a very exciting time in our history, and our ambition is to be the next leader in eye care. We're off to a strong start. By many measures, we already are among the eye care leaders. And that's really because we've done things with a different approach. We've had a blueprint for success, and that has really focused on the patient, but also on a number of different elements of execution that we'll talk about today: generating strong evidence, really focused on educating people around those evidence (doctors, patients, payers), ensuring great access, and then continuing a cycle of very positive and strong execution. We're on a great path with Xdemvy, but it's just the first year. By any measure, this is on a blockbuster path. Our task is to continue to show that, and we're very excited to do that in 2025. With ocular rosacea, we could not be more excited about this opportunity: another opportunity to serve patients that's just like DB, hiding in plain sight, but one that we uniquely can pioneer and develop a new therapy around. We've got a really strong foundation with Xdemvy. It's the first and only approved drug for Demodex blepharitis, an entirely new and fast-growing category in eye care. As we looked at DB, we saw the stars aligning. We saw a disease where we had a root cause, mites causing the disease. We had a precise and easy diagnosis, a slit lamp that we all sit in and get examined in. And all we had to do was have doctors look down, have patients look down to see this disease. And we had a very motivating disease, a chronic progressive disease leading to poor outcomes. So we knew that if we could serve that with a great therapy, as we've done in Xdemvy, we would have a really important medicine for patients. And that focus on the patient has led to our success so far. We've served over 100,000 patients in just the first three quarters of 2024. We have engaged and had prescriptions from nearly our entire prescribing base, over 13,000 of the 15,000 doctors. Really importantly and rarely, we've secured broad and complete coverage. We had the last two Medicare payers come on board, and we entered '25 with broad coverage. That has led to a very strong sales trajectory: $113 million in the first three quarters. You've seen the progress in Q4. We're not going to talk about that today. But we know that in just the first year, Xdemvy has been one of the rare blockbusters in front of the eye and one of the few blockbusters by independent biotech companies. So we're very proud of that early success, but we're not resting on that. We have nine million patients we want to serve. We've only served over 100,000. That starts with the 1.5 million that have DB. We know about MGD and the impact that Xdemvy can have there based on some groundbreaking data, and we're hearing a lot of interest from physicians. And then we have three other really important patient groups that are already seeing the eye doctor and motivated and that have DB: dry eye, cataract surgery, contact lens patients. So by any measure, this is a big blockbuster opportunity, and there is no chance that we're going to run out of patients. So with our evidence, our focus on evidence, we are proud to now see additional benefit for patients for Xdemvy by treating MGD. MGD is a disease where the oily layer of the eye is inadequate. The glands are not secreting the right amount of oil. And we were able to show in our MGD studies in DB that we could improve the function of glands, but also improve patient outcomes, improve how patients look, redness, how they feel, itching and burning, and how they see with fluctuating vision, which is important in MGD, but important in all those other segments I described. With that great tailwind of evidence, and there's more to come that we'll talk about, with very strong access, broad coverage now for all of the patients experiencing this disease, and a very talented sales force, we have an incredible year of growth ahead of us. I'm in the field with these really talented salespeople. They come from eye care. They come from great launch experience, and they're so motivated to serve all the patients they can in the clinics. Time and again, they see and I see with them that every doctor can get to daily prescribing. That approach with frequency and depth is what we're laser-focused on. We've already seen doctors moving from initial use to monthly prescribing to weekly prescribing, and ultimately to daily prescribing, because every clinic has patients every day that have DB. Even our very top prescribers, I talk to them as well, and they are motivated to prescribe more, especially now with the additional evidence and access described. There's two big drivers of growth this year. One is that salesforce, and the other is actually getting this message out to patients. 25 million Americans out there suffering that we know we can serve. That means we need to make, and we'll make Xdemvy a household name. We have just started that direct-to-consumer campaign with streaming TV in the fourth quarter. We've seen a good response there. You've seen that with the weekly script growth. We decided at the start of this year to pilot our first network spots. Those have been high-visibility spots on the Golden Globes, on NFL playoffs. We've also had good coverage across television. We've had daytime and prime-time spots. And we just can't wait to see the impact of that. So expect to talk more about that as we approach Q4 earnings. And we hope and expect that this will lead us to ramp DTC further. So that's where we've come and where we're going in Xdemvy. And let's talk about what's next. I'm so excited about ocular rosacea. We have a blueprint. We can recognize an opportunity like this. And this feels so much like DB in so many ways. So just like DB, the stars have aligned here. We have a disease that's motivating: chronic progressive disease, a disease that was underappreciated because there's never been a therapy, but also one that's caused by mites and one that has objective findings that matter to patients and also to regulators: dilated blood vessels, redness across the eyelid and around the eye, and one that can be easily diagnosed specifically in a slit lamp exam. This is an opportunity where doctors came to us. We were doing lid exams in a way that no company had before, no doctors had before, as they looked for DB, and they started to say, "I'm seeing DB, but I'm also seeing this redness around the eye." And so that led us to say ocular rosacea is a next category in creating opportunity for eye care and for Tarsus. Just like DB, an underappreciated disease because there's been no treatment to date, but a massive population: 15-18 million Americans. Just like DB, a proven blueprint for success, starting with a medicine that really gets to the root cause into the right part of the eye, in this case, a sterile ophthalmic gel that's easy to use for patients and really delivers a best-in-class molecule to the mites that are causing this disease, and as we've done with DB, we have a clear path to prove this and then ultimately get the medicine approved. We have strong relationships with the ophthalmic division at the FDA. We said we're going to engage them, and we have, and what they've told us is we can look at those objective measures of disease that matter: the redness and the dilated blood vessels, those we know are tied to mites. We're speeding this forward to a Phase 2 later this year. We have high confidence in that, given the root cause and the endpoints. With success there, we have a pathway to an approval. In so many ways, an opportunity that's right for Tarsus that really Tarsus can uniquely own and create a new category around. The Tarsus opportunity has never been more real. I've never been more excited about our growth. We've seen the trajectory in 2024. Just imagine what this will look like next year with the growth levers we've described. We're not stopping with Xdemvy and ocular rosacea. We have a blueprint and a team that can create new categories in eye care and serve patients globally. I'll close by saying we've had a strong start. Companies look at us and say, "That's a success in eye care." We're just getting started. We have very strong momentum entering this year that boils down to three things. We're going to accelerate the growth of Xdemvy. We are on a path to create another new category in ocular rosacea. We can do that more in eye care through business development, through leveraging our commercial platform. We can continue to do this over and over again. I know that when we do that, we will be the leading eye care company in the future. I thank you for your time and your interest. I thank many of you that have been along this journey with us for years. I thank the rest of you that are new to this. We look forward to further discussions with you, and we look forward to a great year.